UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934
August
5, 2003
Date of Report (Date of earliest event reported)
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada |
|
0-20045 |
|
95-3872914 |
|
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
|
|
|
|
|
|
|
311 Bonnie Circle |
|
|
|
92880 |
|
(Address of principal executive offices) |
|
|
|
(Zip Code) |
(909) 493-5300
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
c. Exhibits
99.1 News Release titled “Watson Pharmaceuticals Reports Second Quarter 2003 Financial Results” dated August 5, 2003.
Item 12. Results of Operations and Financial Condition.
On August 5, 2003, Watson Pharmaceuticals, Inc. (the Company) issued a news release announcing its financial results for the second quarter ended June 30, 2003. A copy of the Company’s news release is attached hereto as Exhibit 99.1.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: |
August 5, 2003. |
WATSON PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ CHARLES P. SLACIK |
|
|
|
|
Charles P. Slacik |
|
|
|
|
Executive Vice President and |
|
|
|
|
Chief Financial Officer |
3